RET and neoplasm: ctDNA has emerged as a promising biomarker for monitoring treatment response, tracking tumor evolution, and uncovering resistance mechanisms.36,37 In biomarker analysis, SY-5007 demonstrated an impressive ORR of 57.4% in 61 patients with detectable RET alterations, aligning with the radiologic responses across the study populations.